Omics for personalized medicine: defining the current we swim in

Expert Review of Molecular Diagnostics

Volumn 16, Issue 7, 2016, Pages 719-722

  Ibrahim, Rania ^a,b   Pasic, Maria ^a,b   Yousef, George M ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

direct to consumer testing; molecular analysis; next generation sequencing; Omics; overtreatment; Precision medicine; SNPs; tumor markers

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER SCREENING; DIRECT-TO-CONSUMER ADVERTIZING; EDITORIAL; FALSE POSITIVE RESULT; GENETIC DISORDER; GENETIC SCREENING; GENOME ANALYSIS; GENOMICS; HUMAN; NEWBORN SCREENING; PATIENT CARE; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRENATAL DIAGNOSIS; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; DEVICES; PROCEDURES; STANDARDS; TRENDS;

GENOMICS; HUMANS;

EID: 84964050252     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2016.1164601     Document Type: Editorial

References (24)

1. C.Alter Google Seeks Human Guinea Pigs for Health Project [Internet]; 2014 [cited 2015 Nov 7]. Available from: http://time.com/3045429/google-baseline-study-human-health/#3045429/google-baseline-study-human-health/: TIME magazine.
2. A.Li, D.Meyre. Jumping on the train of personalized medicine: A primer for non- geneticist clinicians: Part 3. Clinical applications in the personalized medicine area. Curr Psychiatry Rev. 2014;10(2):118–132.
3. C.McNeil. NCI-MATCH launch highlights new trial design in precision-medicine era. J Natl Cancer Inst. 2015;107:7.
4. M.Flores, G.Glusman, K.Brogaard, et al. P4 medicine: how systems medicine will transform the healthcare sector and society. Per Med. 2013;10(6):565–576.
5. 23andme. 23 and me [Internet]; www.23andme.com. [cited 2015 Oct 5]. Available from: https://www.23andme.com/en-ca/reviews/?utm_source=google&utm_medium=cpc&utm_campaign=CA_Search-Branded&utm_term=can_onepager&utm_content=23c_Search_Paid_Brand&gclid=CLPSi8SN3MkCFYMDaQod7NkLfw.
6. G.M.Yousef. Personalized medicine in kidney cancer: learning how to walk before we run. Eur Urol. 2015;68(6):1021–1022.
7. E.Z.Kontos, K.Viswanath. Cancer-related direct-to-consumer advertising: a critical review. Nat Rev Cancer. 2011;11(2):142–150.
8. J.M.Bollinger, R.C.Green, D.Kaufman. Attitudes about regulation among direct-to-consumer genetic testing customers. Genet Test Mol Biomarkers. 2013;17(5):424–428.
9. M.D.Pasic, S.Samaan, G.M.Yousef. Genomic medicine: new frontiers and new challenges. Clin Chem. 2013;59(1):158–167.
10. N.J.Roberts, J.T.Vogelstein, G.Parmigiani, et al. The predictive capacity of personal genome sequencing. Sci Transl Med. 2012;4(133):133ra58.
11. I.S.Kohane, D.R.Masys, R.B.Altman. The incidentalome: a threat to genomic medicine. Jama. 2006;296(2):212–215.
12. R.C.Green, J.S.Berg, W.W.Grody, et al., et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565–574.
13. E.P.Diamandis, M.Li. The side effects of translational omics: overtesting, overdiagnosis, overtreatment. Clin Chem Lab Med. 2016;54(3):389–396.
14. G.M.Yousef. miRSNP-based approach identifies a miRNA that regulates prostate-specific antigen in an allele-specific manner. Cancer Discov. 2015;5(4):351–352.
15. G.M.Yousef. Personalized cancer genomics: the road map to clinical implementation. Clin Chem. 2012;58(4):661–663.
16. A.Andermann, I.Blancquaert, S.Beauchamp, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317–319.
17. M.Rafiq, C.Ianuale, W.Ricciardi, et al. Direct-to-consumer genetic testing: A systematic review of European guidelines, recommendations, and position statements. Genet Test Mol Biomarkers. 2015;19(10):535–547.
18. H.Rittenhouse, A.Blase, B.Shamel, et al. The long and winding road to FDA approval of a novel prostate cancer test: our story. Clin Chem. 2013;59(1):32–34.
19. P.Autier, M.Boniol, A.Gavin, et al. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. Bmj. 2011;343(jul28 1):d4411.
20. I.Schrijver, N.Aziz, D.H.Farkas, et al., et al. Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the association for molecular pathology. Journal Molecular Diagnostics: JMD. 2012;14(6):525–540.
21. Y.Bombard. Translating personalized genomic medicine into clinical practice: evidence, values, and health policy. Genome National Research Council Canada = Génome Conseil National De Recherches Canada. 2015;58(12):491–497.
22. F.Collins. Has the revolution arrived? Nature. 2010;464(7289):674–675.
23. M.J.Joyner, P.N.Paneth. Seven questions for personalized medicine. Jama. 2015;314(10):999–1000.
24. E.P.Diamandis. The hundred person wellness project and google’s baseline study: medical revolution or unnecessary and potentially harmful over-testing? BMC Med. 2015;13(1):5.